Elon, Inc.: Robotaxi's Underwhelming Texas Rollout
Over the weekend, while the world was transfixed by war in the Middle East, the Tesla Robotaxi quietly appeared on the streets of Austin, Texas. It didn't stay quiet for long, though. As a handful of Tesla influencers filmed themselves driven through the streets of the red state's famously blue capital, their smartphone videos caught plenty of traffic violations. In this week's episode of Elon, Inc. host David Papadopoulos is joined by Bloomberg Businessweek senior writer Max Chafkin as well as Bloomberg electric vehicles reporter Kara Carlson to break down the launch. Years in the making, and with rivals like Waymo already familiar sights in some big US cities, will Elon Musk be able to spin this as something other than a tepid attempt at catch-up? Tesla investors seem to think so: the stock jumped 8.2% on Monday. Papadopoulos and Chafkin are then joined by Bloomberg social media reporter Kurt Wagner, just back from the Cannes Lions International Festival of Creativity. Wagner discusses X's participation, or rather absence, from the all-important advertising event, and goes through how Musk's embattled social media platform has reportedly tried to strong-arm advertisers to return by threatening lawsuits. This prompted Papadopoulos to speculate about the equivalent situation for hot dog vendors or shovel salesmen. Lastly, the crew discuss a few additional news item from the week, namely an exploding SpaceX rocket and the recent report that Musk doesn't use a computer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
29 minutes ago
- Fast Company
These are the top 10 emerging technologies of 2025, according to the World Economic Forum
Breakthroughs happen all the time in the tech world, but only a select few manage to make a lasting impact. Predicting which innovations will shape the future is always a challenge. On Tuesday, the World Economic Forum (WEF) released its list of the top 10 emerging technologies of 2025, highlighting those expected to influence global challenges within the next three to five years. The list, compiled with the help of Frontiers Media, a publisher of peer-reviewed scientific journals, avoids naming specific companies. Instead, the WEF focuses on concepts that are both novel and nearing maturity, with the potential to deliver meaningful benefits to society. Here's what the WEF sees as being on the path to a breakthrough in 2025. Advanced nuclear tech Demand for nuclear energy is on the rise, with the Trump administration pledging to fast-track permits for nuclear projects. The WEF predicts that smaller nuclear designs and alternative cooling systems will offer safer, cleaner energy at a lower cost. These reactors, it says, 'could play a key role in building reliable, zero-carbon power systems.' Structural battery composites The weight of batteries has been a pain point for things like cars and planes, impacting their efficiency. New materials that store energy and support weight can make these vehicles lighter, improving both their performance and their environmental impact. Collaborative sensing Speaking of vehicles, networking connected sensors can let vehicles share information in real time with each other, as well as with cities and emergency services. In the case of an incident, this can reduce traffic, increase response times, and improve safety, the WEF says. Generative watermarking As artificial intelligence becomes even more widespread, distinguishing original content from AI-generated material will be critical. Generative watermarking adds an invisible tag to AI content, helping combat misinformation and build consumer trust. Green nitrogen Producing fertilizer today requires fossil fuels, which leads to pollution and carbon emissions. Green nitrogen, which relies on electricity instead, could offer 'a more sustainable way to grow food,' the WEF says. GLP-1 drugs for neurodegenerative diseases GLP-1 drugs are currently used to treat obesity and diabetes. The WEF notes they are also showing promise in treating other diseases, such as Alzheimer's and Parkinson's. Autonomous biochemical sensing Smart sensors capable of continuously monitoring environmental changes or human health without wires could unlock numerous possibilities. The medical field may use them for early disease detection, while scientists can apply them to track pollution and atmospheric trends. Nanozymes Naturally occurring enzymes help clean pollution and are used in medical diagnostics. Lab-made versions, called nanozymes, are stronger and cheaper, which could expand their use in a variety of applications. Engineered living therapeutics Long-term medical care is expensive and often inconsistent in its results. Scientists, according to the WEF, are developing therapies that use beneficial bacteria to deliver treatments from within the body. This approach could lower costs and improve success rates. Osmotic power systems This renewable energy source, which uses the pressure difference that occurs when freshwater and saltwater mix, produces a cleaner form of electricity. That can be especially helpful in coastal areas where special care must be taken to protect both the environment and wildlife.
Medscape
29 minutes ago
- Medscape
Rapid Review Quiz: Wearable Health Tech
As wearable health technology becomes more sophisticated and accessible, its impact on disease detection, chronic condition management, and preventive care is growing rapidly. From smartwatches that flag abnormal heart rhythms to headbands that analyze sleep stages and wristbands that monitor blood pressure around the clock, these devices are reshaping the landscape of modern healthcare. However, clinical accuracy can vary significantly across devices. How well do you understand the strengths and shortcomings of these wearable health devices? Check your knowledge with this quick quiz. The Apple Watch is US Food and Drug Administration (FDA) approved for over-the-counter use as ECG software to help detect cardiac arrhythmias. In May 2024, the FDA qualified Apple's Atrial Fibrillation History Feature as a Medical Device Development Tool (MDDT). This makes it the first over-the-counter wearable tech accepted under the MDDT program for estimating AF burden in clinical research. The feature might serve as a biomarker to evaluate cardiac interventions, such as ablation therapies, during clinical trials. A new meta-analysis shows that the Apple Watch ECG has high sensitivity and specificity for AF detection compared to standard ECGs. However, expert guidelines and the study itself recommend that providers use the Apple Watch ECG as a screening tool, not for definitive diagnosis. Any positive or suspicious result should be confirmed with a standard 12-lead ECG, which remains the criterion standard for AF diagnosis and can detect other arrhythmias. Choosing to use the Apple Watch ECG as the sole diagnostic tool ignores its limitations and the need for comprehensive evaluation, potentially missing important cardiac conditions. Advising against all use of the device would overlook its value for early and convenient AF screening, especially in at-risk or hard-to-reach populations. Replacing standard ECGs entirely with the Apple Watch is not supported because the Apple Watch cannot provide the full range of diagnostic information. Learn more about AF. A clinical trial showed that after 3 months of using the Dexcom G6, participants had notable improvements in glycemic control. Usage remained high throughout the study, with 91% completing the full 90-day period and wearing the sensor 88% of the time. Compared to fingerstick monitoring, CGM users had lower average glucose levels (184.0-147.2 mg/dL), better time in range (58%-83%), and slight improvements in glucose variability. Additional health benefits included reductions in A1c, BMI, blood pressure (BP), cholesterol, and a lower estimated 10-year cardiovascular risk. Real-world data also confirmed that patients with poorly controlled type 2 diabetes using CGM for 12 months saw continued improvement in glycemic control, especially when using alert features. This was confirmed in a meta-analysis of randomized controlled trials, which concluded that feedback from CGM positively affects glycemic control in adults, regardless of diabetes status. In March 2024, the FDA approved Dexcom's Stelo Glucose Biosensor System, the first over-the-counter CGM, designed for adults with type 2 diabetes not using insulin and for the general public interested in tracking glucose patterns related to lifestyle factors. Learn more about CGM. The Dreem headband uses portable EEG and motion detection for home-based sleep tracking. A recent study comparing Dreem to polysomnography (PSG) (the criterion standard for detailed sleep analysis) found mixed accuracy across sleep metrics. Total sleep time and sleep efficiency aligned closely with PSG results due to the device's ability to detect sleep-wake transitions via movement. However, REM sleep was overestimated by about 25 minutes. Overestimating REM could delay detection of disorders such as Alzheimer's disease and depression (in which sleep disruptions are linked), making the Dreem less reliable for clinical diagnoses that require precise REM data. Although the device shows potential for general sleep monitoring at home, its limitations (especially in identifying REM) suggest that further validation and algorithm refinement are needed, particularly for use in older adults and people with neurodegenerative conditions. Learn more about sleep EEG. A new meta-analysis concluded that wearable activity tracker-based interventions significantly increased daily step counts in older adults compared to usual care (such as prescribed physical activity), highlighting their potential to boost physical activity in this population. Higher step counts are linked to lower cardiovascular mortality and all-cause mortality and reduced frailty risk. The interventions did not significantly improve BMI or functional mobility (Timed Up and Go test) or reduce sedentary time. These outcomes might require longer interventions or additional components such as dietary changes or targeted exercises. Learn more about risk factors for coronary artery disease. Hilo, formerly known as Aktiia (Neuchâtel, Switzerland) is a wearable device that measures BP continuously without a cuff, using optical sensors in a wrist-worn bracelet. It has received regulatory approval in the European Union and Canada. A new study found that Hilo (Aktiia) closely matched ABPM readings during daytime and across a full 24-hour cycle. However, it consistently recorded higher systolic BP at night, indicating reduced accuracy during sleep. It nonetheless captured overall nighttime dipping trends. No major discrepancies were found in daytime readings, and claims of inaccuracy during the day were unfounded. The device also did not show overestimation across all periods, only at night. Furthermore, it successfully tracked dipping patterns, supporting its use with some caution for nighttime data interpretation. Learn more about BP assessment.
Yahoo
30 minutes ago
- Yahoo
Middle Eastern Penny Stocks: 3 Picks With Market Caps Over US$50M
The Middle Eastern stock markets have recently experienced a positive shift, buoyed by the Iran-Israel ceasefire, which has improved investor sentiment and risk appetite across the region. As investors navigate these evolving conditions, penny stocks continue to capture attention due to their potential for growth at lower price points. Despite being considered a somewhat outdated term, penny stocks represent an investment area where smaller or newer companies with strong financials can offer significant opportunities for returns. Name Share Price Market Cap Financial Health Rating Terminal X Online (TASE:TRX) ₪4.959 ₪629.82M ★★★★★★ Menara Ventures Xl - Limited Partnership (TASE:MNRA) ₪2.716 ₪12.48M ★★★★★★ Thob Al Aseel (SASE:4012) SAR3.99 SAR1.6B ★★★★★★ Alarum Technologies (TASE:ALAR) ₪4.693 ₪329.39M ★★★★★★ E7 Group PJSC (ADX:E7) AED1.09 AED2.16B ★★★★★★ Katmerciler Arac Üstü Ekipman Sanayi ve Ticaret (IBSE:KATMR) TRY1.83 TRY1.97B ★★★★★☆ Dubai National Insurance & Reinsurance (P.S.C.) (DFM:DNIR) AED3.14 AED403.1M ★★★★★★ Dubai Investments PJSC (DFM:DIC) AED2.46 AED10.5B ★★★★☆☆ Sharjah Cement and Industrial Development (PJSC) (ADX:SCIDC) AED0.769 AED467.75M ★★★★★★ Tgi Infrastructures (TASE:TGI) ₪2.50 ₪185.86M ★★★★★★ Click here to see the full list of 79 stocks from our Middle Eastern Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Apex Investment PSC is engaged in the manufacturing, distribution, and sale of clinkers and cement products both within the United Arab Emirates and internationally, with a market capitalization of AED13.61 billion. Operations: The company's revenue is derived from catering (AED600.69 million), contracting (AED40.20 million), manufacturing (AED222.78 million), and facility management services (AED107.89 million). Market Cap: AED13.61B Apex Investment PSC, with a market capitalization of AED13.61 billion, recently reported a net loss of AED25.6 million for Q1 2025 despite generating sales of AED196.41 million. The company has managed to remain debt-free and maintains strong liquidity with short-term assets significantly exceeding liabilities. However, its profit margins have declined from 17.6% to 5.4% over the past year, impacted by a large one-off loss of AED79.7 million in the last twelve months ending March 31, 2025. Despite these challenges, Apex's experienced board and stable weekly volatility offer some stability amidst negative earnings growth. Take a closer look at Apex Investment PSC's potential here in our financial health report. Gain insights into Apex Investment PSC's historical outcomes by reviewing our past performance report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Ihlas Gazetecilik A.S. operates in the publishing industry by producing and distributing newspapers, books, encyclopedias, brochures, and magazines both in Turkey and internationally, with a market cap of TRY1.08 billion. Operations: The company generates revenue of TRY1.76 billion from its newspaper publishing segment. Market Cap: TRY1.08B Ihlas Gazetecilik A.S., with a market cap of TRY1.08 billion, has recently become profitable, though its earnings growth is challenging to compare due to past losses. The company reported Q1 2025 sales of TRY481.26 million but faced a net loss of TRY62 million, down from TRY111.3 million the previous year. While its debt-to-equity ratio has significantly improved over five years and short-term assets cover both short- and long-term liabilities, negative operating cash flow indicates that debt isn't well covered by cash flow alone. Despite these challenges, the board's experience provides some governance stability amidst financial volatility. Get an in-depth perspective on Ihlas Gazetecilik's performance by reading our balance sheet health report here. Review our historical performance report to gain insights into Ihlas Gazetecilik's track record. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Tgi Infrastructures Ltd, with a market cap of ₪185.86 million, operates in Israel's automotive industry by producing, processing, assembling, and marketing mechanical assemblies made of magnesium through its subsidiary. Operations: TASE:TGI generates revenue through its Infrastructure and Energy segment, which accounts for ₪82.70 million, and The Metal and Electrical Industries segment, contributing ₪81.87 million. Market Cap: ₪185.86M Tgi Infrastructures Ltd, with a market cap of ₪185.86 million, operates in Israel's automotive industry and has demonstrated robust earnings growth, surpassing the Auto Components industry's average. The company's recent quarterly results show increased sales of ₪43.04 million and net income rising to ₪5.49 million from last year's figures. Tgi's financial health is supported by strong short-term asset coverage over liabilities and satisfactory debt management, as evidenced by a reduced debt-to-equity ratio over five years. However, its 8.64% dividend yield isn't well covered by earnings or cash flows, indicating potential sustainability concerns for investors seeking stable income sources from this stock. Unlock comprehensive insights into our analysis of Tgi Infrastructures stock in this financial health report. Assess Tgi Infrastructures' previous results with our detailed historical performance reports. Embark on your investment journey to our 79 Middle Eastern Penny Stocks selection here. Want To Explore Some Alternatives? The end of cancer? These 24 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ADX:APEX IBSE:IHGZT and TASE:TGI. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
